6th March 2018
Portfolio
This post references, or is about Autolus. Find out more by clicking below
Stay Updated
Add your email below to stay updated with useful and informative content from Arix and our portfolio companies
Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, today notes that its Group Business Autolus Limited has confidentially submitted a draft registration statement on Form F-1 to the U.S. Securities and Exchange Commission relating to a potential initial public offering of ordinary shares in the United States. The timing and the terms of this potential initial public offering have not yet been determined and are subject to market conditions and other factors.